Holen Sie sich die Stockscreener-App
3.28
1.55%
0.05
Schlusskurs vom Vortag:
$3.23
Offen:
$3.29
24-Stunden-Volumen:
57,021
Relative Volume:
0.30
Marktkapitalisierung:
$156.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-293.42M
KGV:
-0.1125
EPS:
-29.1639
Netto-Cashflow:
$-14.87M
1W Leistung:
-3.53%
1M Leistung:
-26.79%
6M Leistung:
-37.88%
1J Leistung:
+55.75%
1-Tages-Spanne:
$3.22
$3.365
1-Wochen-Bereich:
$3.17
$3.50
52-Wochen-Spanne:
$2.08
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
3.28 | 162.34M | 0 | -293.42M | -14.87M | -29.16 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citizens | Mkt Outperform |
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Live Minerva Neurosciences, Inc (NERV) Technical Analysis - Traders Union
Minerva Neurosciences, Inc (NERV) Stock Price History & Data - Traders Union
Minerva Neurosciences Inc Share PriceNERV, RNS News, Articles, Quotes, & Charts (NASDAQ:NERV) - Proactive financial news
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to S&P Global BMI Index - marketscreener.com
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Nigeria
Minerva Neurosciences Inc (NASDAQ: NERV) Share Price, NERV Stock News, NERV Share Price & Updates - Kalkine
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageRevenue Breakdown Analysis - siam.in
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Investing News Network
Minerva (NERV): Loses 0.62% to Close at $4.81 in Latest Trading; Level Watch: the $4.57 to $5.05 Range Remains in Focus for the Current SessionBearish Pattern Stocks - careplusvn.com
Balyasny Asset Management L.P. Expands Stake in Minerva Neurosciences Inc (NERV) - GuruFocus
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Jefferies Upgrades Minerva Neurosciences(NERV.US) to Buy Rating, Raises Target Price to $10 - Moomoo
Jefferies Maintains Minerva Neurosciences(NERV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsHot Stock Picks - vinanet.vn
Minerva Neurosciences (NERV) Plunges 9% to $3.92: Critical Support Level in FocusWyckoff Upthrust - dars.gov.et
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain - Stock Titan
Minerva's schizophrenia trial is designed to enroll 380 patients - Stock Titan
10-Q: Minerva Neurosciences | 10-Q: Q2 2026 Earnings Report - Moomoo
Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV - MarketBeat
Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock Titan
NERV Q2'26 Earnings: EPS estimate is (0.19) USD - TradingView
889,254 Shares in Minerva Neurosciences, Inc $NERV Bought by DV Trading LLC - MarketBeat
NERV Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NERV|Minerva Neurosciences Inc|Price:4.205| - TradingKey
Minerva Neurosciences Inc (NERV) Cash Flow - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Minerva Neurosciences Inc Revenue Breakdown – FWB:4MNA - TradingView
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):